James M. Daly - 29 May 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: Director
Issuer ticker: ACAD
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 18:00:05 UTC
Prior SEC filing: 27 May 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

James M. Daly filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 01 Jun 2026.

Key facts

This page summarizes James M. Daly's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 01 Jun 2026, 18:00.

Change

Previous filing in this sequence was filed on 27 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001560782 Primary reporting owner

Daly James M

Relationship: Director
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,107
Change %: +201%
Price
Shares after: 12,148
Date: 29 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACAD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -8,107
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,107
Exercise price
Footnotes: F1, F2

ACAD transaction Derivative

Director Stock Options (Right to Buy)

Award

Transaction value
Shares: +16,004
Change %
Price: $0.000000^*
Shares after: 16,004
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,004
Exercise price: $21.66
Footnotes: F3

ACAD transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +9,311
Change %
Price: $0.000000^*
Shares after: 9,311
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,311
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Footnote F2

The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.

Footnote F3

The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Footnote F4

The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.